A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)

Dementia With Lewy Bodies (DLB) Clinical Trial

Official title:
Double-blind Study of E2020 in Patients With Dementia With Lewy Bodies - Phase II

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with Dementia with Lewy Bodies (DLB).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00543855
Study type	Interventional
Source	Eisai Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	November 2007
Completion date	February 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04001517` - Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies	Phase 2
Recruiting	`NCT03030586` - ADDIA Proof-of-Performance Clinical Study
Completed	`NCT00776347` - Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)	N/A
Withdrawn	`NCT04055532` - Biomarkers in Neurodegenerative Diseases
Completed	`NCT01278407` - A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase	Phase 3
Completed	`NCT00598650` - A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies	Phase 2